Potassium Chloride 10 meq Tablet, Film Coated, Extended Release, 500-count
Other active recalls for Potassium Chloride (different manufacturers) — 6 · tap to view
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Potassium class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
Potassium is essential for the proper functioning of the heart, kidneys, muscles, nerves, and digestive system. Usually the food you eat supplies all of the potassium you need. However, certain diseases (e.g., kidney disease and gastrointestinal disease with vomiting and diarrhea) and drugs, especially diuretics ('water pills'), remove potassium from the body. Potassium supplements are taken to replace potassium losses and prevent potassium deficiency. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.
Read the full MedlinePlus article ↗- You're right that food is the first line — bananas, potatoes, and leafy greens are all rich in potassium. But sometimes diet alone isn't enough, especially if you're taking a diure...
- Why did my doctor prescribe potassium chloride? I thought potassium just came from bananas.
- Yes — always take oral tablets or capsules with a meal or right after eating. Taking them on an empty stomach can irritate or even ulcerate the lining of your stomach or intestines...
- Do I have to take it with food? What happens if I forget?
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Potassium Chloride (prescription drug) — tap one for details:
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
💊 What it looks like
Where does this data come from?
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 7Z8S9VYZ4B
Ethylcellulose is a plant-derived thickener and film-former made by chemically modifying cellulose. It's used as a binder to hold tablet ingredients together, a coating to control how quickly medicine is released, or a thickener in liquid formulations.
-
UNII 1K09F3G675
Ferric oxide red is an inorganic iron compound used as a colorant in medicines. It gives tablets, capsules, or other dosage forms a red or reddish tint for identification and appearance.
-
UNII EX438O2MRT
Ferric oxide yellow is a naturally occurring iron compound used as a colorant in medications. It gives tablets, capsules, and other forms a yellow or golden hue for identification and appearance.
-
UNII 70097M6I30
Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
-
UNII 3WJQ0SDW1A
Polyethylene glycol is a synthetic liquid or solid polymer used in medicines as a solvent, lubricant, and humectant. It helps dissolve active ingredients, reduces friction during manufacturing, and retains moisture in the final product.
-
UNII 532B59J990
Polyvinyl alcohol is a synthetic polymer made from plant-derived materials. It's used as a binder to hold ingredients together, a film-former in coatings, and a thickener in liquid formulations.
-
UNII 4ELV7Z65AP
Stearic acid is a fatty acid derived from plant or animal sources. It acts as a binder and lubricant in tablets and capsules, helping them hold together and flow smoothly during manufacturing.
-
UNII 7SEV7J4R1U
A powder made from a naturally occurring mineral. In medicines, talc works as a glidant and anti-caking agent, helping tablets and capsules flow smoothly during manufacturing and preventing clumping.
-
UNII 15FIX9V2JP
Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.
9 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per ea | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.083 | $41.40 / 500 tablets |
| Medicaid paysCMS SDUD · 12 mo | $0.2541 | $127.05 / 500 tablets |
| Medicare drug plans payPart D · Q2 2026 | $0.1839 | $91.95 / 500 tablets |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Potassium Chloride 10 meqthis 00378-4561-05 | Mylan | 500 tablets | $0.083 | AB2 | Availability likely | — |
| Potassium Chloride 750 mg 00832-5323-10 | Upsher-Smith | 1000 tablets | $0.083 | AB2 | Availability likely | — |
| Potassium Chloride 750 mg 00904-7216-61 | Major | 1 tablet | $0.083 | AB2 | Availability likely | — |
| Potassium Chloride Extended Release 750 mg 16571-0843-01 | Rising | 100 tablets | $0.083 | AB2 | Availability likely | — |
| Potassium Chloride Extended-Release 750 mg 24979-0231-01 | Upsher-Smith | 100 tablets | $0.083 | AB3 | Availability likely | — |
| Potassium Chloride 750 mg 42806-0423-01 | Epic | 100 tablets | $0.083 | AB2 | Availability likely | — |
| Potassium Chloride 750 mg 60687-0810-09 | American | 1 tablet | $0.083 | AB2 | Availability likely | — |
| Potassium Chloride 750 mg 64380-0861-06 | Strides | 100 tablets | $0.083 | AB2 | Availability likely | — |
| Potassium Chloride 750 mg 65862-0987-01 | Aurobindo | 100 tablets | $0.083 | AB2 | Availability likely | — |
| Potassium Chloride 750 mg 68001-0518-00 | BluePoint | 100 tablets | $0.083 | AB2 | Availability likely | — |
| Potassium Chloride Extended Release 750 mg 70010-0022-01 | Granules | 100 tablets | $0.083 | AB2 | Availability likely | — |
| Potassium chloride 750 mg 72888-0075-00 | Advagen | 1000 tablets | $0.083 | — | Availability likely | — |
| Potassium Chloride 750 mg 70436-0002-01 | Slate | 100 tablets | $0.110 | AB2 | FDA listed | +33% |
| Klor-Con 750 mg 00245-0836-11 | Upsher-Smith | 100 tablets | $0.121 | AB2 | Availability likely | +46% |
| Klor-Con 750 mg 00245-5316-01 | Upsher-Smith | 1 tablet | $0.121 | AB2 | Availability likely | +46% |
| Potassium Chloride 10 meq 62037-0710-01 | Actavis | 100 tablets | $0.135 | AB1 | Discontinued | +63% |
| Potassium Chloride 10 meq 43386-0915-01 | Lupin | 100 tablets | $0.150 | AB1 | FDA listed | +81% |
| Potassium Chloride 750 mg 00615-8570-05 | NCS | 15 tablets | — | AB2 | FDA listed | — |
| Potassium Chloride 750 mg 24979-0230-00 | Upsher-Smith | 64000 tablets | — | AB2 | FDA listed | — |
| Potassium chloride 750 mg 33342-0418-11 | Macleods | 100 tablets | — | AB2 | FDA listed | — |
| Potassium Chloride 750 mg 42291-0487-01 | AvKARE | 100 tablets | — | AB2 | FDA listed | — |
| Potassium Chloride 750 mg 42291-0506-01 | AvKARE | 100 tablets | — | AB2 | FDA listed | — |
| Potassium Chloride 750 mg 50090-5335-00 | A-S | 30 tablets | — | AB2 | FDA listed | — |
| Potassium Chloride 10 meq 50090-6635-00 | A-S | 90 tablets | — | AB2 | FDA listed | — |
| Potassium Chloride Extended-Release 750 mg 50090-6639-00 | A-S | 30 tablets | — | AB3 | FDA listed | — |
| Potassium Chloride Extended-Release 750 mg 50090-6640-00 | A-S | 90 tablets | — | AB3 | FDA listed | — |
| Potassium Chloride 750 mg 50090-7378-00 | A-S | 30 tablets | — | AB2 | FDA listed | — |
| Potassium Chloride 750 mg 50090-7379-00 | A-S | 90 tablets | — | AB2 | FDA listed | — |
| Potassium Chloride 750 mg 50090-7639-00 | A-S | 30 tablets | — | AB2 | FDA listed | — |
| Potassium Chloride 750 mg 50090-7640-00 | A-S | 90 tablets | — | AB2 | FDA listed | — |
| Potassium chloride 750 mg 50090-7748-00 | A-S | 30 tablets | — | — | FDA listed | — |
| Potassium chloride 750 mg 50090-7749-00 | A-S | 90 tablets | — | — | FDA listed | — |
| Potassium Chloride 750 mg 51655-0226-26 | Northwind | 90 tablets | — | AB2 | FDA listed | — |
| Potassium Chloride 750 mg 51655-0463-84 | Northwind | 14 tablets | — | AB2 | FDA listed | — |
| Potassium Chloride 750 mg 51655-0706-52 | Northwind | 30 tablets | — | AB2 | FDA listed | — |
| Potassium Chloride 750 mg 60760-0423-90 | St. | 90 tablets | — | AB2 | FDA listed | — |
| Potassium chloride extended release 750 mg 63629-8442-01 | Bryant | 100 tablets | — | AB2 | Discontinued | — |
| Potassium Chloride 750 mg 68788-8262-03 | Preferred | 30 tablets | — | AB2 | FDA listed | — |
| Potassium Chloride 750 mg 70436-0152-01 | Slate | 100 tablets | — | AB3 | FDA listed | — |
| Potassium Chloride 750 mg 70518-2964-00 | REMEDYREPACK | 30 tablets | — | AB2 | FDA listed | — |
| Potassium Chloride Extended Release 750 mg 70518-4520-00 | REMEDYREPACK | 30 tablets | — | AB2 | FDA listed | — |
| Potassium Chloride 750 mg 71335-1131-01 | Bryant | 30 tablets | — | AB2 | FDA listed | — |
| Potassium Chloride Extended-Release 750 mg 71335-2447-01 | Bryant | 30 tablets | — | AB3 | FDA listed | — |
| Potassium Chloride 750 mg 71610-0349-15 | Aphena | 15 tablets | — | AB2 | FDA listed | — |
| Potassium Chloride Extended Release 750 mg 71610-0932-60 | Aphena | 90 tablets | — | AB2 | FDA listed | — |
| Potassium Chloride Extended-Release 750 mg 71610-0935-60 | Aphena | 90 tablets | — | AB3 | FDA listed | — |
| Potassium Chloride 750 mg 71610-0944-30 | Aphena | 30 tablets | — | AB2 | FDA listed | — |
| Potassium Chloride 750 mg 71610-0945-30 | Aphena | 30 tablets | — | AB2 | FDA listed | — |
| Potassium chloride 750 mg 71610-0960-60 | Aphena | 90 tablets | — | — | FDA listed | — |
| Potassium Chloride 750 mg 71610-0977-30 | Aphena | 30 tablets | — | AB2 | FDA listed | — |
| Potassium Chloride 750 mg 72189-0027-04 | Direct_Rx | 4 tablets | — | AB2 | FDA listed | — |
| Potassium chloride 750 mg 72789-0503-95 | PD-Rx | 1000 tablets | — | — | FDA listed | — |
| Potassium Chloride 750 mg 82804-0187-30 | Proficient | 30 tablets | — | AB2 | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
🗺️ Medicaid utilization & spend
💊 Medicaid utilization by pack size
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
🔬 Reported adverse events (FAERS)
Top reported reactions
Reporter sex
Serious outcomes
Where does this data come from?
📦 Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Status |
|---|---|---|---|---|---|
| 00378-4561-05 You're viewing this | 500 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0378-4561-05) | $0.0828 / ea | $41.40 | 2016-11-09 | Active |
| 00378-4561-77 | 90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0378-4561-77) | $0.0828 / ea | $7.45 | 2016-11-09 | Active |
You're viewing the largest of 2 pack sizes for this product.
This pack has the lowest per-ea cost of the 2 priced pack sizes ($0.0828 NADAC).
In Medicaid, this is the most-dispensed pack of this product — about 92% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in NDC 00378-4561-05?
What is the difference between NDC 00378-4561-05 and NDC 00378-4561-77?
What NDC number is used to bill for this package of Potassium Chloride 10 meq Tablet, Film Coated, Extended Release?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE Potassium chloride extended-release tablets are indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. Potassium chloride extended-release tablets are a potassium salt, indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.
( 1 )
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION • Monitor serum potassium and adjust dosages accordingly ( 2.1 ) • If serum potassium is less than 2.5 mEq/L, use intravenous potassium instead of oral supplementation ( 2.1 ) • Take with meals and with a glass of water or other liquid. Swallow tablets whole without crushing, chewing or sucking. ( 2.1 ) • Treatment of hypokalemia: Doses range from 40-100 mEq/day in divided doses.
Limit doses to 40 mEq per dose. ( 2.2 ) • Prevention of hypokalemia: Typical dose is 20 mEq per day. ( 2.2 )
2.1Administration and Monitoring If serum potassium concentration is less than 2.5 mEq/L, use intravenous potassium instead of oral supplementation. Monitoring Monitor serum potassium and adjust dosages accordingly. Monitor serum potassium periodically during maintenance therapy to ensure potassium remains in desired range.
The treatment of potassium depletion, particularly in the presence of cardiac disease, renal disease, or acidosis, requires careful attention to acid-base balance, volume status, electrolytes, including magnesium, sodium, chloride, phosphate, and calcium, electrocardiograms, and the clinical status of the patient. Correct volume status, acid-base balance, and electrolyte deficits as appropriate. Administration Take potassium chloride extended-release tablets with meals and with a glass of water or other liquid.
Do not take potassium chloride extended-release tablets on an empty stomach because of their potential for gastric irritation [see Warnings and Precautions (5.1) ] . Swallow tablets whole without crushing, chewing or sucking.
2.2Dosing Dosage must be adjusted to the individual needs of each patient. Dosages greater than 40 mEq per day should be divided such that no more than 40 mEq is given in a single dose. Treatment of Hypokalemia Typical dose range is 40-100 mEq per day. Maintenance or Prophylaxis Typical dose range is 20 mEq per day.
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS Potassium Chloride Extended-Release Tablets, USP are available containing 600 mg or 750 mg of potassium chloride, USP (equivalent to 8 mEq or 10 mEq, respectively). • The 8 mEq (600 mg) tablets are light brown, film-coated, round, unscored tablets debossed with M on one side of the tablet and PC2 on the other side. • The 10 mEq (750 mg) tablets are peach, film-coated, round, unscored tablets debossed with M on one side of the tablet and PC1 on the other side. Tablets: 600 mg (8 mEq) and 750 mg (10 mEq) ( 3 )
⛔ Contraindications ▾
4 CONTRAINDICATIONS Potassium chloride is contraindicated in patients on triamterene and amiloride. • Concomitant use with triamterene and amiloride ( 4 )
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS • Gastrointestinal Irritation: Take with meals ( 5.1 )
5.1Gastrointestinal Adverse Reactions Solid oral dosage forms of potassium chloride can produce ulcerative and/or stenotic lesions of the gastrointestinal tract, particularly if the drug maintains contact with the gastrointestinal mucosa for prolonged periods. Consider the use of liquid potassium in patients with dysphagia, swallowing disorders, or severe gastrointestinal motility disorders. If severe vomiting, abdominal pain, distention, or gastrointestinal bleeding occurs, discontinue potassium chloride extended-release tablets and consider possibility of ulceration, obstruction or perforation.
Potassium chloride extended-release tablets should not be taken on an empty stomach because of their potential for gastric irritation [see Dosage and Administration (2.1) ] .
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS The following adverse reactions have been identified with use of oral potassium salts. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The most common adverse reactions to oral potassium salts are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea.
There have been reports of hyperkalemia and of upper and lower gastrointestinal conditions including obstruction, bleeding, ulceration, perforation. Skin rash has been reported rarely. • The most common adverse reactions are nausea, vomiting, flatulence, abdominal pain/discomfort and diarrhea. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
🔄 Drug Interactions ▾
7 DRUG INTERACTIONS • Triamterene and amiloride: Concomitant use is contraindicated ( 7.1 ) • Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7.2 ) • Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 )
7.1Triamterene or Amiloride Use with triamterene or amiloride can produce severe hyperkalemia. Concomitant use is contraindicated [see Contraindications (4) ] .
7.2Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients on concomitant RAAS inhibitors.
7.3Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDS may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients on concomitant NSAIDs.
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS • Cirrhosis: Initiate therapy at the low end of the dosing range ( 8.6 ) • Renal Impairment: Initiate therapy at the low end of the dosing range ( 8.7 )
8.1Pregnancy Risk Summary There are no human data related to use of potassium chloride extended-release tablets during pregnancy, and animal reproduction studies have not been conducted. Potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. The background risk for major birth defects and miscarriage in the indicated population is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
8.2Lactation Risk Summary The normal potassium ion content of human milk is about 13 mEq per liter. Since oral potassium becomes part of the body potassium pool, so long as body potassium is not excessive, the contribution of potassium chloride supplementation should have little or no effect on the level in human milk.
8.4Pediatric Use Safety and effectiveness in the pediatric population have not been established.
8.5Geriatric Use Clinical studies of potassium chloride extended-release tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
8.6Cirrhotics Based on published literature, the baseline corrected serum concentrations of potassium measured over 3 hours after administration in cirrhotic subjects who received an oral potassium load rose to approximately twice that of normal subjects who received the same load. Patients with cirrhosis should usually be started at the low end of the dosing range, and the serum potassium level should be monitored frequently [see Clinical Pharmacology (12.3) ] .
8.7Renal Impairment Patients with renal impairment have reduced urinary excretion of potassium and are at substantially increased risk of hyperkalemia. Patients with impaired renal function, particularly if the patient is on RAAS inhibitors or NSAIDs, should usually be started at the low end of the dosing range because of the potential for development of hyperkalemia [see Drug Interactions (7.2 , 7.3) ] . The serum potassium level should be monitored frequently.
Renal function should be assessed periodically.
🤰 Pregnancy ▾
8.1Pregnancy Risk Summary There are no human data related to use of potassium chloride extended-release tablets during pregnancy, and animal reproduction studies have not been conducted. Potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. The background risk for major birth defects and miscarriage in the indicated population is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
🧒 Pediatric Use ▾
8.4Pediatric Use Safety and effectiveness in the pediatric population have not been established.
🧓 Geriatric Use ▾
8.5Geriatric Use Clinical studies of potassium chloride extended-release tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
🆘 Overdosage ▾
10 OVERDOSAGE
10.1Symptoms The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired, potentially fatal hyperkalemia can result [see CONTRAINDICATIONS and WARNINGS ] . It is important to recognize that hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration (6.5 to 8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-wave, depression of S-T segment and prolongation of the QT interval).
Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).
10.2Treatment Treatment measures for hyperkalemia include the following: 1. Elimination of foods and medications containing potassium and of any agents with potassium-sparing properties. 2.
Intravenous administration of 300 to 500 mL/hr of 10% dextrose solution containing 10 to 20 units of crystalline insulin per 1,000 mL. 3. Correction of acidosis, if present, with intravenous sodium bicarbonate.
4. Use of exchange resins, hemodialysis or peritoneal dialysis. In treating hyperkalemia, it should be recalled that in patients who have been stabilized on digitalis, too rapid a lowering of the serum potassium concentration can produce digitalis toxicity.
The extended release feature means that absorption and toxic effects may be delayed for hours. Consider standard measures to remove any unabsorbed drug.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action The potassium ion is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle and the maintenance of normal renal function. The intracellular concentration of potassium is approximately 150 to 160 mEq per liter.
The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane. Potassium is a normal dietary constituent and under steady state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine.
The usual dietary intake of potassium is 50 to 100 mEq per day.
12.3Pharmacokinetics The potassium chloride in potassium chloride extended-release tablets is completely absorbed before it leaves the small intestine. The matrix is not absorbed and is excreted in the feces; in some instances the empty matrices may be noticeable in the stool. When the bioavailability of the potassium ion from the potassium chloride extended-release tablets is compared to that of a true solution the extent of absorption is similar.
The extended-release properties of potassium chloride extended-release tablets are demonstrated by the finding that a significant increase in time is required for renal excretion of the first 50% of the potassium chloride extended-release tablets dose as compared to the solution. Increased urinary potassium excretion is first observed 1 hour after administration of potassium chloride extended-release tablets, reaches a peak at approximately 4 hours, and extends up to 8 hours. Mean daily steady-state plasma levels of potassium following daily administration of potassium chloride extended-release tablets cannot be distinguished from those following administration of potassium chloride solution or from control plasma levels of potassium ion.
Specific Populations Cirrhotics Based on published literature, the baseline corrected serum concentrations of potassium measured over 3 hours after administration in cirrhotic subjects who received an oral potassium load rose to approximately twice that of normal subjects who received the same load.
🧬 Mechanism of Action ▾
12.1Mechanism of Action The potassium ion is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle and the maintenance of normal renal function. The intracellular concentration of potassium is approximately 150 to 160 mEq per liter.
The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane. Potassium is a normal dietary constituent and under steady state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine.
The usual dietary intake of potassium is 50 to 100 mEq per day.
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING Potassium Chloride Extended-Release Tablets, USP are available containing 600 mg or 750 mg of potassium chloride (equivalent to 8 mEq or 10 mEq, respectively). The 8 mEq (600 mg) tablets are light brown, film-coated, round, unscored tablets debossed with M on one side of the tablet and PC2 on the other side. They are available as follows: NDC 0378-4560-77 bottles of 90 tablets NDC 0378-4560-05 bottles of 500 tablets The 10 mEq (750 mg) tablets are peach, film-coated, round, unscored tablets debossed with M on one side of the tablet and PC1 on the other side.
They are available as follows: NDC 0378-4561-77 bottles of 90 tablets NDC 0378-4561-05 bottles of 500 tablets Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from light and moisture. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.
📋 Description ▾
11 DESCRIPTION Potassium Chloride Extended-Release Tablets, USP are a solid oral dosage form of potassium chloride. Each contains 600 mg or 750 mg of potassium chloride equivalent to 8 mEq or 10 mEq of potassium in a matrix tablet. Potassium Chloride Extended-Release Tablets are an electrolyte replenisher.
The chemical name is potassium chloride, and the structural formula is KCl. Potassium chloride, USP is a colorless, elongated, prismatic or cubical crystals, or white granular powder. It is odorless and has a saline taste.
Its solutions are neutral to litmus. It is freely soluble in water and insoluble in alcohol. Inactive Ingredients: Ethylcellulose, magnesium stearate, polyethylene glycol, polyvinyl alcohol, red iron oxide, stearic acid, talc, titanium dioxide and yellow iron oxide.
Meets USP Assay Sample Preparation 2.
💬 Information for Patients ▾
17 PATIENT COUNSELING INFORMATION • Inform patients to take each dose with meals and with a full glass of water or other liquid, and to not crush, chew, or suck the tablets. Inform patients that the matrix is not absorbed and is excreted in the feces; in some instances the empty matrices may be noticeable in the stool. • Advise patients seek medical attention if tarry stools or other evidence of gastrointestinal bleeding is noticed. Manufactured for: Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A. Manufactured by: Mylan Laboratories Limited Hyderabad – 500 096, India 75075455 Revised: 4/2020 MX:KCHLER:R4